Previous close | 2.4000 |
Open | 2.4200 |
Bid | 2.3700 x 1000 |
Ask | 2.3900 x 800 |
Day's range | 2.2800 - 2.5000 |
52-week range | 1.3500 - 9.0750 |
Volume | |
Avg. volume | 279,870 |
Market cap | 134.28M |
Beta (5Y monthly) | 1.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.9230 |
Earnings date | 22 Feb 2023 - 27 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.00 |
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib. Entospletinib is Kronos Bio's lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute